Key result
Olmesartan medoxomil, with or without hydrochlorothiazide, effectively reduces blood pressure and enables a majority of patients with stage 1 hypertension to achieve blood pressure goals.
Why the study?
Does olmesartan medoxomil alone or with hydrochlorothiazide improve blood pressure lowering and goal achievement in patients with stage 1 hypertension?
Does olmesartan medoxomil alone or with hydrochlorothiazide improve blood pressure lowering and goal achievement in patients with stage 1 hypertension?
This review of 5 studies supports olmesartan medoxomil-based therapy as an effective and safe option for achieving guideline-directed blood pressure goals in patients with stage 1 hypertension.
Answers are grounded in this paper and cite their sources.
May support olmesartan-based regimens for stage 1 hypertension; leaves open need for randomized confirmation.
Hypertension is a known risk factor for cardiovascular events and mortality. The risk of cardiovascular events increases with age and is linear above 115/75 mm Hg. It also doubles for every 20/10-mm Hg elevation beyond this level and at every age level. Although guidelines vary somewhat by country, the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommends a blood pressure (BP) goal of < 140/90 mm Hg for patients with uncomplicated hypertension and < 130/80 mm Hg for patients with type 2 diabetes mellitus (T2DM) or renal disease. Based on clinical evidence, patients with stage 1 hypertension (seated cuff systolic BP of 140-159 mm Hg or diastolic BP of 90-99 mm Hg) should be treated to targeted BP levels to reduce cardiovascular morbidity and mortality. The angiotensin II receptor blockers (ARBs) are well tolerated and demonstrate significant BP reduction. Olmesartan medoxomil (OM), an ARB, has been well studied and achieves significant BP lowering and goal achievement with good tolerability. Moreover, combination therapy comprising OM plus hydrochlorothiazide can significantly increase BP goal achievement without significantly increasing adverse events. This review evaluates clinical efficacy and safety data from 5 OM-based studies: 4 dose-titration studies and 1 factorial study. Study results demonstrate that OM ± hydrochlorothiazide is highly effective in reducing BP while enabling a majority of patients with stage 1 hypertension to achieve BP goal. In addition, OM tolerability data showed that the high achievement of BP goals was not attained at the expense of increased adverse events. This treatment is associated with low discontinuation rates, even in elderly patients and individuals with T2DM. The clinical data presented in this review support OM-based therapy as a rational and safe therapeutic option for patients with stage 1 hypertension.
No takes yet. Share an insight, caveat, or question.
F. Wilford Germino (2010) conducted a review in Stage 1 hypertension. Olmesartan medoxomil ± hydrochlorothiazide was evaluated on Blood pressure reduction and goal achievement. Olmesartan medoxomil, with or without hydrochlorothiazide, effectively reduces blood pressure and enables a majority of patients with stage 1 hypertension to achieve blood pressure goals.
Synapse has enriched 10 related papers. Consider them for comparative context: